Archive for the ‘FDA Appropriations’ Category
Sunday, July 18th, 2010
On July 1, the House Appropriations Agriculture/FDA Subcommittee marked up it FY 11 bill. The bottomline was good for FDA: $2.571 billion, a $214 million increase over FY 10, about 9%. No further details will be released until the full committee marks up, possibly later this month.
On July 15, the Senate Appropriations Committee marked up its version of the Agriculture/FDA funding bill. The good news is that the Senate agreed that FDA needs better funding….and provided $2.516 billion, a $158 million in new monies. This is a bit more than 6%. Here is FDA Matters’ analysis of this critical budget battle. (more…)
Tweet This Post
Posted in FDA Appropriations, FDA and Congress | No Comments »
Thursday, May 27th, 2010
May 18 marked one year since Dr. Margaret Hamburg was sworn in as Commissioner of the US Food and Drug Administration. The challenges are great, the torrent of issues is never-ending and most days you can smile but you can’t win. Nonetheless, I think it has been a very good first year for her and for Principal Deputy Commissioner, Dr. Joshua Sharfstein.
It may seem premature to be discussing “the Hamburg legacy.” But you know that she is thinking about it (all commissioners do), so why can’t FDA Matters talk about it? (more…)
Tweet This Post
Posted in FDA Appropriations, FDA Leadership, FDA and Congress, FDA and Industry, Planning for FDA's Future | No Comments »
Sunday, April 25th, 2010
Several times this year, I have been told: FDA’s food activities have been getting most of the new monies at the expense of human drugs (CDER) and biologics (CBER). But is it true that food activities (mostly CFSAN, the Center for Food Science and Applied Nutrition) are receiving preferred treatment?
FDA Matters ran the numbers to see. We conclude that center-envy is bad in its own right, but even worse when it is based on misinformation and misperceptions. (more…)
Tweet This Post
Posted in FDA Appropriations, FDA Leadership, FDA and Congress | No Comments »
Sunday, March 28th, 2010
FDA touches every American many times each day. Today’s investment (2 cents per day per American) is a pittance compared to the benefit of a strong FDA and the risk of an underfunded FDA. There cannot be many agencies in the US government that have such a vast scope of responsibilities and so few dollars to get the job done.
This is the powerful message that the Alliance for a Stronger FDA has been delivering to Capitol Hill. Even still, it will be a difficult year for any federal agency whose mission and responsibilities are growing. (more…)
Tweet This Post
Posted in FDA Appropriations, FDA Leadership, FDA and Congress | No Comments »
Sunday, March 7th, 2010
The President’s proposal to freeze domestic discretionary programs in FY 2011 (and beyond) will force painful cuts across government and in programs that millions of American rely upon. Even some traditionally-favored agencies, such as NIH, are looking at only small increases. With a proposed 6% increase (about $150 million), FDA would seem to be doing far better than most.
FDA Matters feels strongly that this is not nearly enough. By my calculations, at least a $250 million increase for FDA would be needed, just to achieve the program levels anticipated in the President’s budget request. The Alliance for a Stronger FDA has asked for a $495 million increase, which could be put to good use by the agency. Why is 6% not enough? (more…)
Tweet This Post
Posted in FDA Appropriations, FDA and Congress, Planning for FDA's Future | No Comments »
Thursday, February 4th, 2010
The President’s FY 11 budget request for FDA includes a $146 million increase in appropriated (non-user fee) funding. This is about 6% of the $2.36 billion appropriation that FDA received in FY 10. With the President’s tough talk about deficit reduction, anything above a freeze should be considered good. Why was the Alliance for a Stronger FDA disappointed? (more…)
Tweet This Post
Posted in FDA Appropriations, FDA and Congress, Planning for FDA's Future | No Comments »
Thursday, January 28th, 2010
The President’s State of the Union (SOTU) address gave no clues as to the fate of the FDA budget for FY 11 (begins October 1, 2010). Both the general and specific details for the agency await the February 1 release of the President’s budget request.
While the House and Senate have control over the final amount that FDA receives, the President’s request is the baseline against which the Congress works. FDA Matters is pleased to offer a guide to interpreting this first stage of the FY 11 appropriations process. (more…)
Tweet This Post
Posted in FDA Appropriations, FDA and Congress | 1 Comment »
Sunday, January 24th, 2010
The election of Massachusetts’ new Senator, Scott Brown, has set off a media frenzy about the fate of health care reform legislation. However, the ramifications of his election reach far beyond health reform.
FDA turns out to be a good example. FDA Matters sees at least three consequences of his election that may affect the agency in 2010. (more…)
Tweet This Post
Posted in FDA Appropriations, FDA and Congress, Follow-on Biologics | No Comments »
Sunday, December 6th, 2009
Tradition says nothing happens between Thanksgiving and New Year’s Day. People check out mentally and, as often as possible, physically. Not this December, not in Washington, DC.
Most attention is on the US Senate, which is working this weekend and remains under threat of “no days off” until healthcare reform legislation passes. Just as intensely, but much less visibly, the Executive Branch is working full-tilt to complete the President’s Budget Request for FY 11 prior to the State of the Union speech in late January.
Of the two December activities, the President’s budget is far more important to FDA. (more…)
Tweet This Post
Posted in FDA Appropriations, FDA and Congress, Planning for FDA's Future | No Comments »
Tuesday, October 6th, 2009
There is good news to report now that House-Senate conferees have finalized work on FDA’s FY 10 budget. FDA received $306 million (15%) more to spend this fiscal year. Every center will have more resources to work with (see table at the bottom of this article).
This is the third good year for FDA, after years of bad ones. The agency is still severely underfunded, but progress is finally being made. Now the hard work begins: spending the new money wisely and showing that it has been used to accomplish important public health missions. (more…)
Tweet This Post
Posted in FDA Appropriations, FDA Leadership, FDA and Congress | No Comments »
© 2009-2010 by HPS Group. All rights reserved. Permission is hereby granted to those wishing to quote or reprint from this site, providing it is properly attributed to
FDA Matters: The Grossman FDA Report™.
